MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
BörsenkürzelMDXH
Name des UnternehmensMDxHealth SA
IPO-datumJun 26, 2006
CEOMr. Michael K. McGarrity
Anzahl der mitarbeiter312
WertpapierartOrdinary Share
GeschäftsjahresendeJun 26
AddresseCAP Business Center
StadtHERSTAL
BörseNASDAQ Capital Market Consolidated
LandBelgium
Postleitzahl4040
Telefon3243642070
Websitehttps://mdxhealth.com/
BörsenkürzelMDXH
IPO-datumJun 26, 2006
CEOMr. Michael K. McGarrity
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten